The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous InterventionA TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38) Analysis
Michelle O'Donoghue, MD*,*,
Elliott M. Antman, MD*,
Eugene Braunwald, MD*,
Sabina A. Murphy, MPH*,
P. Gabriel Steg, MD ,
Ariel Finkelstein, MD||,
William F. Penny, MD ,
Viliam Fridrich, MD ,
Carolyn H. McCabe, BSc*,
Marc S. Sabatine, MD, MPH* and
Stephen D. Wiviott, MD*
* TIMI Study Group, Brigham and Women's Hospital, Boston, Massachusetts
INSERM U-698, Université Paris 7, AP-HP, Paris, France
University of California, San Diego/VA Medical Center, San Diego, California
Slovak Institute of Cardiovascular Disease, Bratislava, Slovakia
|| Tel-Aviv Medical Center, Tel-Aviv, Israel
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Kaplan-Meier Curves Demonstrating the Efficacy of Prasugrel Versus Clopidogrel
Kaplan-Meier curves demonstrating the efficacy of prasugrel versus clopidogrel for reducing cardiovascular (CV) death, myocardial infarction (MI), or stroke by 30 days stratified by the use of a glycoprotein (GP) IIb/IIIa inhibitor during index hospitalization (pinteraction = 0.83). CI = confidence interval; HR = hazard ratio.
|
|
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Efficacy Outcomes Through 30 Days' Follow-Up Stratified by the Use of a GP IIb/IIIa Inhibitor During Index Hospitalization
Kaplan-Meier (K-M) event rates, HR (95% CI), and p values for the interaction between subgroups are shown. Data markers are weighted for size of subgroup. *Periprocedural MI is defined as occurring <48 h after PCI or CABG. CABG = coronary artery bypass graft surgery; CVD = cardiovascular death; PCI = percutaneous coronary intervention; other abbreviations as in Figure 1.
|
|
|
